• PDF / 182,312 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 9 Downloads / 181 Views

DOWNLOAD

REPORT

---

1 S

Allergic reaction and Pneumocystis jirovecii pneumonia: 7 case reports In a retrospective study of 649 patients, who underwent allogeneic hematopoietic cell transplantation between 1 January 2008 and 30 June 2017 in Canada, 7 patients [including a 63-year-old woman* ; not all ages and sexes stated] were described, who developed Pneumocystis jirovecii pneumonia or allergic reaction during treatment with antithymocyte globulin or dapsone [not all routes and duration of treatments to reactions onsets stated; outcomes not stated]. The patients underwent allogeneic haematopoietic cell transplantation and received antithymocyte globulin [Thymoglobulin] 0.5 mg/kg on day -2, 2 mg/kg on day -1 and 2 mg/kg on day 0 before graft infusion for graft-versus-host disease prophylaxis (7 patients). Of these 7 patients, one patient received oral dapsone, and 3 patients received pentamidine for Pneumocystis jirovecii pneumonia prophylaxis. Subsequently, 3 of the 7 patients developed Pneumocystis jirovecii pneumonia 431–792 days after transplantation, and 3 patients developed Pneumocystis jirovecii pneumonia 30–203 days after initiation of pentamidine. One of the 7 patients developed allergic reaction secondary to the use of dapsone for Pneumocystis jirovecii pneumonia prophylaxis; the patient’s treatment with dapsone was therefore changed to pentamidine. * Identifying patients details (age and sex) have been obtained through direct communication with the author. Evernden C, et al. High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era. Cytotherapy 22: 27-34, No. 1, Jan 2020. Available from: URL: http://doi.org/10.1016/j.jcyt.2019.11.002 803498143

0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 29 Aug 2020 No. 1819